Better Health for All

Lannett Company, Inc. manufactures over 100 unique pharmaceutical product families, which are described as safe, effective, and life-enhancing generic products.

Two products, Ranitidine Syrup and Levetiracetam Oral Solution, were subject to voluntary recalls in late 2019 due to safety concerns, representing less than 5% of its product families. , The company demonstrated good risk transparency by notifying the FDA of potential issues, initiating testing, and communicating recalls to distributors and customers via email and its website. , As a pharmaceutical company, its operations do not involve nutrition and food safety.

Fair Money & Economic Opportunity

The provided articles describe Lannett Company Inc. as a pharmaceutical company that develops, manufactures, and distributes generic prescription products

. The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess financial institutions on aspects such as lending, fees, financial literacy, and access to financial services. The articles do not contain any specific, concrete data points or information related to Lannett's involvement in financial services or any of the criteria outlined in the rubric for this value. Therefore, all KPIs are omitted due to a lack of relevant evidence.

Fair Pay & Worker Respect

In 2022, Lannett Company Inc. reported a CEO median pay ratio of 43:1.

This ratio is derived from CEO Timothy Crew's total compensation of $3,532,372 and a median employee pay of $82,124.

Fair Trade & Ethical Sourcing

No specific, quantitative data points were found in the provided articles to assess Lannett Company Inc. against the 'Fair Trade & Ethical Sourcing' KPIs. While a Supplier Code of Conduct exists, outlining policies on child labor and the right to cancel orders for violations

, and the company complies with DSCSA for drug tracing , the articles do not provide percentages for fair-trade certification, audit frequency, number of forced/child labor incidents, traceability coverage for suppliers, remediation speed, ethical clause coverage in contracts, share of high-risk materials, or supplier diversity spend.

Honest & Fair Business

No specific, concrete evidence was found in the provided articles to assess Lannett Company Inc. against any of the 'Honest & Fair Business' KPIs. Information regarding regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflicts of interest, anti-corruption policy strength and enforcement, or third-party verification of ethical claims was not available.

While a Supplier Code of Conduct was mentioned, it outlines requirements for suppliers rather than detailing the company's own internal policy strength and enforcement for anti-corruption.

Kind to Animals

Lannett Company Inc. engages in animal testing as part of its drug development process.

This includes toxicology studies in Sprague-Dawley rats and mice for Cocaine Hydrochloride Topical Solution , and an Animal PK Study for insulin aspart . There is no explicit statement of an animal testing policy , nor is there any mention of the use of alternative, non-animal testing methods in the provided information .

No War, No Weapons

Lannett Company Inc (LCI.US) is a pharmaceutical company, and its core business description does not involve defense or arms-related activities. There is no evidence of revenue from arms contracts, dual-use technology development, or military use of AI. The company's lobbying expenditures are explicitly for 'Pharmaceuticals/Health Products,' indicating no defense-related lobbying. The Supplier Code of Conduct lists ethical red lines related to labor practices (e.g., child labor, forced labor) but not those concerning weapons or military activities.

No evidence suggests the company has defense assets to divest, a dual-use portfolio, or involvement in surveillance or intelligence activities. Therefore, for these KPIs, the company's operations are not applicable to the defense sector.

Planet-Friendly Business

Lannett Company's inaugural ESG Report for the 2021 fiscal year was prepared in accordance with the TCFD framework

. A Scope 1 and Scope 2 GHG emissions inventory was developed for the 2021 fiscal year . For FY2021, Q1–Q3, water use per batch was 24.2% higher than FY2020, Q1–Q3 , and 8.4% higher than the 3-year average . Energy consumption per batch for the same period was 14.5% higher than FY2020, Q1–Q3 , and 6.6% higher than the 3-year average . Greenhouse gas emissions per 100 batches for FY2021, Q1–Q3, were 15.4% higher than FY2020, Q1–Q3 , and 2.6% higher than the 3-year average . Conversely, waste disposed per batch for FY2021, Q1–Q3, was 48.3% lower than FY2020, Q1–Q3 , and 36.5% lower than the 3-year average . In FY2020, the company reported decreases in water use per batch (1.1%) , energy usage per batch (0.3%) , and greenhouse gas emissions per batch (5.8%) compared to FY2019, but waste generated per batch increased by 17.2% .

Respect for Cultures & Communities

No relevant data was found in the provided articles to assess LCI.US against the 'Respect for Cultures & Communities' ethical value. and resulted in 404 errors

, , and discussed a securities class action lawsuit against SolarEdge Technologies, not LCI.US .

Safe & Smart Tech

Lannett Company, Inc.'s privacy notice, last updated in January 2018, indicates that users have the option to opt out of certain disclosures or uses of their personal information

. However, the company explicitly states it does not alter its practices when it receives a 'Do Not Track' signal from a visitor’s browser , suggesting limitations in user control over data. The privacy notice references compliance with legal processes and applicable law , specifically mentioning California privacy rights such as the 'Shine the Light' law and California Civil Code Section 1789.3 .

Zero Waste & Sustainable Products

Lannett Company Inc. introduced bulk packaging for 22 products in 43 dosage strengths

, an initiative aimed at reducing waste. No other specific, quantitative evidence was found for waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.